Recombinant Chicken TNFRSF18
Cat.No. : | TNFRSF18-2565C |
Product Overview : | Recombinant Chicken TNFRSF18 full length or partial length protein was expressed. |
- Specification
- Gene Information
- Related Products
- Download
Source : | Mammalian Cells |
Species : | Chicken |
Tag : | His |
Form : | Liquid or lyophilized powder |
Endotoxin : | < 1.0 eu per μg of the protein as determined by the LAL method. |
Purity : | >80% |
Notes : | This item requires custom production and lead time is between 5-9 weeks. We can custom produce according to your specifications. |
Storage : | Store it at +4 oC for short term. For long term storage, store it at -20 oC~-80 oC. |
Storage Buffer : | PBS buffer |
Gene Name : | TNFRSF18 tumor necrosis factor receptor superfamily, member 18 [ Gallus gallus (chicken) ] |
Official Symbol : | TNFRSF18 |
Gene ID : | 419424 |
Protein Refseq : | NP_001026045 |
UniProt ID : | Q5ZMR1 |
Products Types
◆ Recombinant Protein | ||
Tnfrsf18-2770M | Recombinant Mouse Tnfrsf18 Protein, His-tagged | +Inquiry |
TNFRSF18-664R | Recombinant Rat TNFRSF18 Protein | +Inquiry |
TNFRSF18-329H | Recombinant Human TNFRSF18 protein, His-tagged | +Inquiry |
TNFRSF18-663M | Recombinant Mouse TNFRSF18 Protein, Fc-tagged | +Inquiry |
TNFRSF18-154H | Recombinant Human TNFRSF18 Protein, C-His-tagged | +Inquiry |
◆ Lysates | ||
TNFRSF18-1245RCL | Recombinant Rat TNFRSF18 cell lysate | +Inquiry |
TNFRSF18-1143HCL | Recombinant Human TNFRSF18 cell lysate | +Inquiry |
Related Gene
Not For Human Consumption!
Inquiry
- Reviews
- Q&As
Customer Reviews (3)
Write a reviewThis flexibility enables researchers like myself to tailor TNFRSF18 protein experiments to our unique needs, enhancing the reliability and relevance of the obtained results.
Their commitment to delivering exceptional products and assisting with any challenges that may arise ensures a successful and rewarding experimental journey.
The TNFRSF18 protein offered by the manufacturer is of exceptional quality, and it meets the rigorous standards necessary for my experimental needs.
Q&As (5)
Ask a questionClinical trials are investigating TNFRSF18 agonists, such as monoclonal antibodies, in combination with other cancer treatments in various cancer types.
As of my knowledge cutoff date in January 2022, there were no approved TNFRSF18-targeted therapies for cancer. However, this may have changed since then.
Side effects may include immune-related adverse events, similar to those seen with other immunotherapies, and can range from mild to severe.
TNFRSF18-targeted therapies may enhance the body's immune response against cancer cells, leading to better tumor control and improved patient outcomes.
Yes, combination therapies involving TNFRSF18 agonists and other immunotherapies are under investigation to improve treatment efficacy.
Ask a Question for All TNFRSF18 Products
Required fields are marked with *
My Review for All TNFRSF18 Products
Required fields are marked with *
Inquiry Basket